2004

• 21/01/2004

  Opération Tremplin Entreprise 2004

• 21/01/2004

  Wyeth Joins Ingenium’s Genetic Rat Model Program

• 28/01/2004

  Tak'Asik receives $ 16.25 million Series C Funding to Fuel Expansion of its Growing Imaging Processor Business

• 26/01/2004

  Alors que l'essai clinique a franchi un cap, Exonhit Therapeutics attend maintenant les résultats d'efficacité de sa molécule dans le traitement de la sclérose latérale amyotrophique

• 26/01/2004

  Exonhit Therapeutics awaits final efficacy results as amyotrophic lateral sclerosis trial moves forward

• 29/01/2004

  Sofinnova Partners invests in InfraWorlds, a startup destined for a bright future in the wireless entertainment market

• 29/01/2004

  Sofinnova Partners investit dans InfraWorlds, société à fort potentiel

• 09/02/2004

  Sofinnova Partners soutient le développement de 6WIND en participant au deuxième tour de financement de 5 millions d’euros

• 09/02/2004

  Sofinnova Partners announces a €5 million second investment round to support the development of 6WIND

• 16/02/2004

  Cobion acquired by Internet Security Systems

• 25/02/2004

  Diatos S.A. Closes Euro 7 Million in a New Financing Round

• 25/02/2004

  Gruenenthal and Ingenium Enter INGENOtyping™ Agreement

• 26/02/2004

  Esmertec gains a worldwide leadership role in fast growing mobile Java™ markets

• 24/02/2004

  Marconi et CTS annoncent un partenariat

• 24/02/2004

  MARCONI and CTS announce partnership agreement

• 23/02/2004

  SOFINNOVA earmarks €85 million to accelerate activity in European wireless market

• 04/03/2004

  Cell Therapeutics, Inc. To Initiate Pivotal Trial for Pixantrone in Relapsed Aggressive Non-Hodgkin’s Lymphoma

• 08/03/2004

  CareX Completes 25 € million ($US32 million) Series B Private Placement- Funding to support development of diabetes and dyslipidemia therapies -

• 17/03/2004

  Newly Formed UPEK Raises $20 Million in a First Round Financing Led by Sofinnova Ventures and Sofinnova Partners

• 08/03/2004

  CareX réalise un placement privé de série B de 32 millions de dollars (25 millions d’ euros) - Un financement destiné à promouvoir le développement de traitements du diabète et de la dyslipidémie -

• 18/03/2004

  Samsung Electro-Mechanics (SEMCO) selects Varioptic’s electrowetting technology for its camera module products World Premiere at CeBIT

• 29/03/2004

  PolyTechnos Funds and Sofinnova Partners co-lead EUR 10 million Series-B financing round in French Varioptic

• 29/03/2004

  Sofinnova Partners et PolyTechnos Funds investissent 10 millions d’euros pour la deuxième levée de fonds de Varioptic

• 07/04/2004

  Esmertec™ provides Time Warner Cable with JVM solution for the OCAP Market

• 06/04/2004

  Ablynx closes €25 million Series B Financing

• 06/04/2004

  Ablynx lève un second tour de 25 millions d'euros

• 20/04/2004

  Cell Therapeutics Initiates Phase I/II Study of CT-2106

• 21/04/2004

  TRISENOX® U.S. Marketing Exclusivity Extended to 2018 - CTI expands TRISENOX® use in Europe with launch in Italy

• 27/04/2004

  Actelion announces first quarter results 2004

• 03/05/2004

  Vidiom Systems Selects Esmertec™ to provide the JVM solution for its OCAP Products

• 05/05/2004

  Georges Haas, Ph.D., Joins Ingenium’s Supervisory Board Munich, Germany, May 5, 2004

• 10/05/2004

  Faust raises 16 million euros to further develop its product candidates

• 10/05/2004

  Faust Pharmaceuticals lève 16 M d’euros pour développer ses produits en clinique

• 03/05/2004

  Saegis Pharmaceuticals Begins Phase II Clinical Trial of SGS742 for Alzheimer’s Disease

• 28/04/2004

  Saegis Pharmaceuticals Announces Lead Product Candidate SGS742 Improves Cognition in Patients with Mild Cognitive Impairment

• 12/05/2004

  Ingenium Acquires Pivotal Patents for INGENOtypingTM Platform

• 17/05/2004

  Addex Pharmaceuticals Completes Largest ever European Biotech Series B Fund Raising

• 19/05/2004

  Phase II Studies of TRISENOX in Multiple Myeloma and Myelodysplastic Syndrome Yield Promising Results

• 25/05/2004

  Cell Therapeutics, Inc. Completes Enrollment in Second Pivotal Trial of XYOTAX™ in Poor Performance Status (PS2), Non-Small Cell Lung Cancer Patients

• 10/06/2004

  Arsenic Trioxide Highlighted in Seven Presentations at European Hematology Association (EHA) Conference

• 07/06/2004

  Samsung Electro-Mechanics (SEMCO) to provide Varioptic’s liquid lenses for the mobile phones and PDA market

• 22/06/2004

  gamma capital partners and Sofinnova Partners co-lead €3 million series-B financing round in Austrian Pro-Med

• 07/06/2004

  Samsung Electro-Mechanics (SEMCO) fabriquera et commercialisera des lentilles liquides basées sur la technologie de Varioptic pour le marché des terminaux mobiles

• 14/06/2004

  Combination of TRISENOX®, Vitamin C and Low-Dose Melphalan Produces 54 Percent Objective Response Rate in Late-Stage Multiple Myeloma Patients

• 14/06/2004

  TRISENOX® Produces Hematologic Responses in 27 Percent of MDS Patients

• 22/06/2004

  Esmertec to demonstrate new breakthrough Java™ Solution – Jbed™ Advanced during JavaOne 2004

• 22/06/2004

  Esmertec démontrera sa nouvelle solution Java™ CLDC multi-tache Jbed™ Advanced à l'occasion de JavaOne 2004

• 28/06/2004

  Esmertec’s Java™ Virtual Machine (JVM) solution for mobile phones is selected by Panasonic

• 01/07/2004

  Servista, the leading provider of outsourced customer care and billing services for the home services market, has won the contract to support the Post Office's® entry into the UK residential fixed line market.

• 23/06/2004

  Premier Prix Biotech de la Ville de Paris 2004 : Diatos récompensé pour sa stratégie de développement international par la Ville de Paris, la CCIP et BioTeam Paris Region

• 06/07/2004

  Atomz Named to Second-Annual AlwaysOnTM List of Top 100 Private Companies

• 30/06/2004

  NIF Ventures acquires a stake in Varioptic S.A.

• 12/07/2004

  Qosmos reçoit un premier tour de financement de Sofinnova Partners

• 12/07/2004

  Qosmos receives a first round of financing from Sofinnova Partners

• 07/07/2004

  Esmertec ouvre un centre d'assistance clientèle et de test à Taipei (Taiwan)

• 07/07/2004

  Esmertec is opening Customer Support and Testing Centre in Taipei, Taiwan

• 19/07/2004

  Ablynx and Procter&Gamble form nanobody drug discovery and development partnership

• 22/07/2004

  Michel Bon ancien président-directeur général de France Télécom rejoint le Conseil d’administration d’Esmertec

• 20/07/2004

  Breakthrough ReValving(TM) Device Developed by CoreValve, S.A., May Provide Preferred Alternative to Open-Heart Surgery

• 22/07/2004

  Esmertec welcomes Michel Bon, Former CEO and Chairman of France Telecom, to its Board

• 26/07/2004

  Cell Therapeutics, Inc. Completes Enrollment in Third Pivotal Trial of XYOTAX™ in Lung Cancer

• 26/07/2004

  Ingenium INGENOtyping™ Agreement with Bayer HealthCare AG Meets Milestone for Genetic Model Production

• 28/07/2004

  Diatos Elected Among the Top 15 Emerging Biotech Companies of 2004

• 30/07/2004

  6WIND emporers customers and partners with a further commitment to quality

• 02/08/2004

  Les plus hautes performances Java jamais atteintes sur cœur de MIPS32 24Kc

• 02/08/2004

  Highest Java™ Performance Achieved by the MIPS32® 24Kc™ Core

• 27/07/2004

  Esmertec acquires OOVM

• 27/07/2004

  Esmertec acquiert la société OOVM

• 16/08/2004

  Jean Schmitt dans Microméga/RFI

• 09/08/2004

  "Euronext n'a pas la place financière qu'il mérite" Jean-Bernard Schmidt - Les Echos 9 Août 2004 -

• 30/08/2004

  Tony Reis, l’ancien CEO de Swisscom, rejoint le Conseil d’Administration d’Esmertec

• 30/08/2004

  Tony Reis, Former CEO of Swisscom, joins Esmertec’s Board of Directors

• 24/08/2004

  Enfora partners with Esmertec to enable wireless Java technology in their GSM/GPRS OEM devices

• 24/08/2004

  Enfora se rapproche d’Esmertec pour intégrer la technologie Java dans ses terminaux GSM/GPRS

• 16/08/2004

  Intransa secures twenty five million dollars in series D funding

• 06/09/2004

  Sensitive Object secures 2 million € Series A financing round from Sofinnova Partners

• 06/09/2004

  Sofinnova Partners investit 2 millions d’Euros dans le premier tour de financement de Sensitive Object

• 08/09/2004

  Oxxius reçoit un premier financement de 2,4 millions d'euros de Sofinnova Partners

• 14/09/2004

  Le Dr Ulrich Schumacher rejoint le Conseil d’Administration d’Esmertec

• 08/09/2004

  Oxxius receives 2.4 million euros from Sofinnova Partners in first round of financing

• 14/09/2004

  Dr. Ulrich Schumacher joins Esmertec as a Member of the Board of Directors

• 20/09/2004

  Cellzome AG Announces Partnership Agreement with Novartis

• 23/09/2004

  France Télécom choisit Esmertec comme partenaire technologique pour ses plates-formes embarquées Java

• 23/09/2004

  France Telecom selects Esmertec as technology partner for its embedded Java platforms

• 30/09/2004

  ETRI collaborates with Esmertec in R&D for digital home solutions and next generation personal communication devices

• 30/09/2004

  Etri et Esmertec unissent leurs efforts de R&D pour le développement de réseaux domestiques et de la future génération de produits de communication personnels

• 26/10/2004

  Esmertec lève CHF 23.5 Millions par le biais d’obligations convertibles

• 26/10/2004

  Esmertec raises CHF 23.5 Million from convertible note to fund growth

• 26/10/2004

  Intransa annouces IP5500 - The industry's next-generation modular IP san solution for the mid-market

• 10/11/2004

  Varioptic Selected Most Innovative Company of the Year for Its Liquid Lenses

• 10/11/2004

  Varioptic élue Entreprise Innovante de l’année pour ses lentilles liquides

• 18/11/2004

  Rapprochement stratégique entre Esmertec et Mitsui & Co.

• 18/11/2004

  Esmertec Establishes Strategic Relationship with Mitsui & Co.

• 17/11/2004

  Esmertec and arm collaborate to optimize java application performance in wireless and embedded devices

• 22/11/2004

  Ablynx appoints Edwin Moses as chairman of the board of directors

• 23/11/2004

  Sendo choisit la solution Java d’Esmertec’s pour ses téléphones mobiles

• 23/11/2004

  Sendo has chosen Esmertec’s Java solution for its mobile phones

• 23/11/2004

  Arsenic Trioxide and Pixantrone Highlighted in 42 Abstracts and Presentations at The American Society of Hematology Meeting

• 06/12/2004

  Phase I/II Experience of Pixantrone CHOP-Variant (CPOP)

• 05/12/2004

  TRISENOX® Produces Hematologic Responses in 30 Percent of Patients with Higher-Risk MDS

• 09/12/2004

  Esmertec to Integrate Hybrid’s OpenGL ES based Graphics Solutions into its Jbed Solution

• 16/12/2004

  Diatos moves its lead drug, DTS-201, toward clinical trials in Europe

• 23/12/2004

  CropDesign appoints new CEO

• 16/12/2004

  Encouraging Survival Estimates in Non-Small Cell Lung Cancer Push XYOTAX™ Pivotal Trial Data Release to End of First Quarter 2005

• 01/11/2004

  CoreValve : Cath Lab Digest talks with founder Dr. Jacques Seguin about inserting a heart valve prosthesis in the cath lab.

• 16/12/2004

  Esmertec to further secure mobile Java content with SATSA-based implementation from Gemplus

• 16/12/2004

  Esmertec sécurise les contenus des mobiles Java avec l’implémentation SATSA de Gemplus